CI-1011 lowers lipoprotein(a) and plasma cholesterol concentrations in chow-fed cynomolgus monkeys

Atherosclerosis

Volumn 136, Issue 1, 1998, Pages 79-87

  Ramharack, Randy ^a   Spahr, Mark A ^a   Sekerke, Catherine S ^a   Stanfield, Richard L ^a   Bousley, Richard F ^a   Lee, Helen T ^a   Krause, Brian K ^a  

^a PFIZER INC   (United States)

Author keywords

Cholesterol; CI 1011; Cynomolgus monkey; Lipid regulator; Lipoprotein(a)

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; LIPOPROTEIN A; SULFAMIC ACID ((2,4,6 TRIS (1 METHYLETHYL) PHENYL)ACETYL) 2,6 BIS(1 METHYLETHYL) PHENYL ESTER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; MALE; MONKEY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0031875096     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)00189-5     Document Type: Article

References (48)

1. Koschinsky M.L., Ramharack R. Structure, function and regulation of lipoprotein(a). Curr Pharm Des. 2:1996;121-138.
2. Ramharack R., Spahr M.A., Kreick J.S., Sekerke C.S. Expression of apolipoprotein[a] and plasminogen mRNAs in cynomolgus monkey liver and extrahepatic tissues. J Lipid Res. 37:1996;2029-2040.
3. White A.L., Lanford R.E. Cell surface assembly of lipoprotein(a) in primary cultures of baboon hepatocytes. J Biol Chem. 269:1994;28716-28723.
4. Kikuchi S., Nakagawa A., Kobayashi K.et al. High degree of genetic polymorphism in apolipoprotein(a) associated with plasma lipoprotein(a) levels in Japanese and Chinese populations. Hum Genet. 92:1993;537-544.
5. Kraft H.G., Lingenhel A., Pang R.W.et al. Frequency distributions of apolipoprotein(a) kringle IV repeat alleles and their effects on lipoprotein(a) levels in Caucasian, Asian, and African populations: the distribution of null alleles is non-random. Eur J Hum Genet. 4:1996;74-87.
6. Gaw A., Boerwinkle E., Cohen J.C., Hobbs H.H. Comparative analysis of the apo(a) gene, apo(a) glycoprotein, and plasma concentrations of Lp(a) in three ethnic groups. Evidence for no common 'null' allele at the apo(a) locus. J Clin Invest. 93:1994;2526-2534.
7. Utermann G. The mysteries of lipoprotein(a). Science. 246:1989;904-910.
8. Makino K., Scanu A.M. Lipoprotein(a): nonhuman primate models. Lipids. 26:1991;679-683.
9. Dahlen G.H., Guyton J.R., Attar M., Farmer J.A., Kautz J.A., Gotto A.M.J. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 74:1986;758-765.
10. Hoefler G., Harnoncourt F., Paschke E., Mirtl W., Pfeiffer K.H., Kostner G.M. Lipoprotein Lp(a). A risk factor for myocardial infarction. Arteriosclerosis. 8:1988;398-401.
11. Rosengren A., Wilhelmsen L., Eriksson E., Risberg B., Wedel H. Lipoprotein(a) and coronary heart disease: a prospective case-control study in a population sample of middle aged men. Br Med J. 301:1990;1248-1251.
12. Schaefer E.J., Lamon-Fava S., Jenner J.L.et al. Lipoprotein(a) levels and risk of coronary heart disease in men: The lipid research clinics coronary primary prevention trial. J Am Med Assoc. 271:1994;999-1003.
13. Bostom A.G., Cupples L.A., Jenner J.L.et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger - a prospective study. J Am Med Assoc. 276:1996;544-548.
14. Orth-Gomér K., Mittleman M.A., Schenck-Gustafsson K.et al. Lipoprotein(a) as a determinant of coronary heart disease in young women. Circulation. 95:1997;329-334.
15. Hearn J.A., Donohue B.C., Ba'albaki H.et al. Usefulness of serum lipoprotein (a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 69:1992;736-739.
16. Tenda K., Saikawa T., Maeda T.et al. The relationship between serum lipoprotein(a) and restenosis after initial elective percutaneous transluminal coronary angioplasty. Jpn Circ J. 57:1993;789-795.
17. Murai A., Miyahara T., Fujimoto N., Matsuda M., Kameyama M. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis. 59:1986;199-204.
18. Zenker G., Koltringer P., Bone G., Niederkorn K., Pfeiffer K., Jurgens G. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke. 17:1986;942-945.
19. Mölgaard J., Klausen I.C., Lassvik C., Færgeman O., Gerdes L.U., Olsson A.G. Significant association between low-molecular-weight apolipoprotein(a) isoforms and intermittent claudication. Arterioscler Thromb. 12:1992;895-901.
20. Tyrrell J., Cooke T., Reilly M.et al. Lipoprotein [Lp(a)] and peripheral vascular disease. J Intern Med. 232:1992;349-352.
21. Henriksson P., Angelin B., Berglund L. Hormonal regulation of serum Lp(a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma. J Clin Invest. 89:1992;1166-1171.
22. Soma M.R., Osnago-Gadda I., Paoletti R.et al. The lowering of lipoprotein(a) induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med. 153:1993;1462-1468.
23. Sacks F.M., McPherson R., Walsh B.W. Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations. Arch Intern Med. 154:1994;1106-1110.
24. Shewmon D.A., Stock J.L., Rosen C.J.et al. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler Thromb. 14:1994;1586-1593.
25. Berglund L., Carlström K., Stege R.et al. Hormonal regulation of serum lipoprotein (a) levels: effects of parenteral administration of estrogen or testosterone in males. J Clin Endocrinol Metab. 81:1996;2633-2637.
26. Bruschi F., Meschia M., Soma M., Perotti D., Paoletti R., Crosignani P.G. Lipoprotein(a) and other lipids after oophorectomy and estrogen replacement therapy. Obstet Gynecol. 88:1996;950-954.
27. Kim C.J., Ryu W.S., Kwak J.W., Park C.T., Ryoo U.H. Changes in Lp(a) lipoprotein and lipid levels after cessation of female sex hormone production and estrogen replacement therapy. Arch Intern Med. 156:1996;500-504.
28. Taskinen M.R., Puolakka J., Pyörälä T.et al. Hormone replacement therapy lowers plasma Lp(a) concentrations - comparison of cyclic transdermal and continuous estrogen-progestin regimens. Arterioscler Thromb Vasc Biol. 16:1996;1215-1221.
29. Marcovina S.M., Lippi G., Bagatell C.J., Bremner W.J. Testosterone-induced suppression of lipoprotein(a) in normal men; relation to basal lipoprotein(a) level. Atherosclerosis. 122:1996;89-95.
30. Zmuda J.M., Thompson P.D., Dickenson R., Bausserman L.L. Testosterone decreases lipoprotein(a) in men. Am J Cardiol. 77:1996;1244-1247.
31. Albers J.J., Taggart H.M., Applebaum Bowden D., Haffner S., Chesnut C.H., Hazzard W.R. Reduction of lecithin-cholesterol acyltransferase, apolipoprotein D and the Lp(a) lipoprotein with the anabolic steroid stanozolol. Biochim Biophys Acta. 795:1984;293-296.
32. Crook D., Sidhu M., Seed M., O'Donnell M., Stevenson J.C. Lipoprotein Lp(a) levels are reduced by danazol, an anabolic steroid. Atherosclerosis. 92:1992;41-47.
33. Hoppichler F., Sandholzer C., Moncayo R., Utermann G., Kraft H.G. Thyroid hormone (fT4) reduces lipoprotein(a) plasma levels. Atherosclerosis. 115:1995;65-71.
34. Klausen I.C., Hegedüs L., Hansen P.S., Nielsen F.E., Gerdes L.U., Faergeman O. Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with hyperthyroidism. Clin Invest. 73:1995;41-46.
35. Kung A.W.C., Pang R.W.C., Lauder I., Lam K.S.L., Janus E.D. Changes in serum lipoprotein(a) and lipids during treatment of hyperthyroidism. Clin Chem. 41:1995;226-231.
36. Pazos F., Alvarez J.J., Rubiés-Prat J., Varela C., Lasunción M.A. Long term thyroid replacement therapy and levels of lipoprotein(a) and other lipoproteins. J Clin Endocrinol Metab. 80:1995;562-566.
37. Gurakar A., Hoeg J.M., Kostner G., Papadopoulos N.M., Brewer H.B.J. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis. 57:1985;293-301.
38. Ramires J.A.F., Mansur A.P., Solimene M.C.et al. Effect of gemfibrozil versus lovastatin on increased serum lipoprotein(a) levels of patients with hypercholesterolemia. Int J Cardiol. 48:1995;115-120.
39. Ramharack R., Spahr M.S., Hicks G.W.et al. Gemfibrozil significantly lowers cynomolgus monkey plasma lipoprotein(a)-protein and liver apolipoprotein(a) mRNA levels. J Lipid Res. 36:1995;1294-1304.
40. Jones PH, Gotto AM, Pownall HJ, et al. Effect of gemfibrozil on plasma lipoprotein(a) levels in type IIa hyperlipoproteinemic subjects. Circulation 1995;84:II-483.
41. Maggi F.M., Biasi G.M., Catapano A.L. Reduction of Lp(a) plasma levels by bezafibrate. Atherosclerosis. 100:1993;127-128.
42. Bimmermann A., Boerschmann C., Schwartzkopff W., Von Baeyer H., Schleicher J. Effective therapeutic measures for reducing lipoprotein(a) in patients with dyslipidemia. Lipoprotein(a) reduction with sustained-release bezafibrate. Curr Ther Res. 49:1991;635-643.
43. Lee H.T., Sliskovic D.R., Picard J.A.et al. Inhibitors of acyl-CoA:cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets. J Med Chem. 39:1996;5031-5034.
44. Kieft K.A., Bocan T.M., Krause B.R. Rapid on-line determination of cholesterol distribution among plasma lipoproteins after high-performance gel filtration chromatography. J Lipid Res. 32:1991;859-866.
45. Taddei-Peters W.C., Butman B.T., Jones G.R., Venetta T.M., Macomber P.F., Ransom J.H. Quantification of lipoprotein(a) particles containing various apolipoprotein(a) isoforms by a monoclonal anti-apo(a) capture antibody and a polyclonal anti-apolipoprotein B detection antibody sandwich enzyme immunoassay. Clin Chem. 39:1993;1382-1389.
46. MBewu A.D., Durrington P.N. Lipoprotein(a): structure, properties and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis. 85:1990;1-14.
47. Scandinavian Simvastatin Survey Study Group Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet. 345:1995;1274-1275.
48. Shepherd J., Cobbe S.M., Ford I.et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New Engl J Med. 333:1995;1301-1307.